Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1977 Aug;60(2):302–312. doi: 10.1172/JCI108778

Studies on the Mechanism of Ristocetin-Induced Platelet Agglutination

EFFECTS OF STRUCTURAL MODIFICATION OF RISTOCETIN AND VANCOMYCIN

Barry S Coller 1, Harvey R Gralnick 1
PMCID: PMC372370  PMID: 17620

Abstract

The mechanism by which ristocetin induces platelet agglutination in the presence of the von Willebrand factor was studied by chemically altering ristocetin and a similar antibiotic, vancomycin, by reaction with a water-soluble carbodiimide in the presence of glycine methyl ester at pH 4.75. Altering ristocetin's phenolic groups (which are thought to be important in its peptide-binding properties) resulted in a loss of both platelet-agglutinating and antibiotic activities. Restoring the phenolic groups with hydroxylamine restored both activities.

Vancomycin has antibiotic and peptide-binding properties similar to ristocetin's, but differs structurally in having a free carboxyl group and thus a less positive charge at neutral pH. It does not induce platelet agglutination and actually inhibits ristocetin-induced agglutination. Reacting vancomycin with the water-soluble carbodiimide resulted in alteration of phenolic groups and permanent conversion of the carboxyl to a neutral derivative. Restoring the phenolic groups with hydroxylamine (but leaving the carboxyl neutralized) produced a compound with charge properties similar to ristocetin's which induced platelet agglutination as ristocetin does.

These data suggest both a binding requirement (mediated through phenolic groups) and a strong positive charge requirement for ristocetin-induced agglutination. The data are consistent with a model wherein positively charged ristocetin binds, via its phenolic groups, to sites on the platelet surface and reduces the platelet's negative charge. This could reduce the electrostatic repulsion between platelets and/or between platelets and the negatively charged von Willebrand factor, and permit the macromolecular von Willebrand factor to cause agglutination by bridging between platelets.

Full text

PDF
302

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allain J. P., Cooper H. A., Wagner R. H., Brinkhous K. M. Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand factor and platelet aggregating factor. J Lab Clin Med. 1975 Feb;85(2):318–328. [PubMed] [Google Scholar]
  2. Carraway K. L., Koshland D. E., Jr Reaction of tyrosine residues in proteins with carbodiimide reagents. Biochim Biophys Acta. 1968 Jun 26;160(2):272–274. doi: 10.1016/0005-2795(68)90102-5. [DOI] [PubMed] [Google Scholar]
  3. Coller B. S., Franza B. R., Jr, Gralnick H. R. The pH dependence of quantitative ristocetin-induced platelet aggregation: theoretical and practical implications-a new device for maintenance of platelet-rich plasma pH. Blood. 1976 May;47(5):841–854. [PubMed] [Google Scholar]
  4. Coller B. S., Gralnick H. R. The effect of stir bar size and shape on quantitative platelet aggregation. Thromb Res. 1976 Feb;8(2):121–129. doi: 10.1016/0049-3848(76)90255-3. [DOI] [PubMed] [Google Scholar]
  5. Coller B. S., Hirschman R. J., Gralnick H. R. Studies on the Factor VIII/von Willebrand factor antigen on human platelets. Thromb Res. 1975 Jun;6(6):469–480. doi: 10.1016/0049-3848(75)90059-6. [DOI] [PubMed] [Google Scholar]
  6. Coller B. S., Lundberg W. B., Gralnick H. R. Effects of vancomycin on platelets, plasma proteins and hepatitis B surface antigen. Thromb Diath Haemorrh. 1975 Sep 30;34(1):83–93. [PubMed] [Google Scholar]
  7. Dawber J. G., Roberts J. C. An electrical double layer theory for platelet adhesiveness and initiation of intravascular thrombosis. Thromb Diath Haemorrh. 1968 Jul 31;19(3):451–458. [PubMed] [Google Scholar]
  8. Gralnick H. R., Coller B. S. Studies of the human factor VIII/von Willebrand's factor protein. II. Identification and characterization of the von Willebrand protein. Blood. 1975 Sep;46(3):417–430. [PubMed] [Google Scholar]
  9. Gralnick H. R., Coller B. S., Sultan Y. Carbohydrate deficiency of the factor VIII/von Willebrand factor Protein in von Willebrand's disease variants. Science. 1976 Apr 2;192(4234):56–59. doi: 10.1126/science.1083071. [DOI] [PubMed] [Google Scholar]
  10. Green D., Potter E. V. Platelet-bound ristocetin aggregation factor in normal subjects and patients with von Willebrand's disease. J Lab Clin Med. 1976 Jun;87(6):976–986. [PubMed] [Google Scholar]
  11. Greenberg J., Packham M. A., Cazenave J. P., Reimers H. J., Mustard J. F. Effects on platelet function of removal of platelet sialic acid by neuraminidase. Lab Invest. 1975 Apr;32(4):476–484. [PubMed] [Google Scholar]
  12. Gröttum K. A., Solum N. O. Congenital thrombocytopenia with giant platelets: a defect in the platelet membrane. Br J Haematol. 1969 Mar;16(3):277–290. doi: 10.1111/j.1365-2141.1969.tb00402.x. [DOI] [PubMed] [Google Scholar]
  13. Hoare D. G., Koshland D. E., Jr A method for the quantitative modification and estimation of carboxylic acid groups in proteins. J Biol Chem. 1967 May 25;242(10):2447–2453. [PubMed] [Google Scholar]
  14. Howard M. A., Firkin B. G. Ristocetin--a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh. 1971 Oct 31;26(2):362–369. [PubMed] [Google Scholar]
  15. Howard M. A. Inhibition and reversal of ristocetin - induced platelet aggregation. Thromb Res. 1975 Jun;6(6):489–499. doi: 10.1016/0049-3848(75)90061-4. [DOI] [PubMed] [Google Scholar]
  16. Howard M. A., Montgomery D. C., Hardisty R. M. Factor-VIII-related antigen in platelets. Thromb Res. 1974 May;4(5):617–624. doi: 10.1016/0049-3848(74)90218-7. [DOI] [PubMed] [Google Scholar]
  17. Jenkins C. S., Phillips D. R., Clemetson K. J., Meyer D., Larrieu M. J., Lüscher E. F. Platelet membrane glycoproteins implicated in ristocetin-induced aggregation. Studies of the proteins on platelets from patients with Bernard-Soulier syndrome and von Willebrand's disease. J Clin Invest. 1976 Jan;57(1):112–124. doi: 10.1172/JCI108251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. KIRBY W. M., DIVELBISS C. L. Vancomycin; clinical and laboratory studies. Antibiot Annu. 1956:107–117. [PubMed] [Google Scholar]
  19. Kattlove H. E., Gomez M. H. Studies on the mechanism of ristocetin-induced platelet aggregation. Blood. 1975 Jan;45(1):91–96. [PubMed] [Google Scholar]
  20. Kirby E. P. Evans blue: a specific inhibitor of factor VIII-induced platelet agglutination. Thromb Diath Haemorrh. 1975 Dec 15;34(3):770–779. [PubMed] [Google Scholar]
  21. Kirby E. P., Mills D. C. The interaction of bovine factor VIII with human platelets. J Clin Invest. 1975 Aug;56(2):491–502. doi: 10.1172/JCI108116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Legaz M. E., Schmer G., Counts R. B., Davie E. W. Isolation and characterization of human Factor VIII (antihemophilic factor). J Biol Chem. 1973 Jun 10;248(11):3946–3955. [PubMed] [Google Scholar]
  23. Meyer D., Jenkins C. S., Dreyfus M. D., Fressinaud E., Larrieu M. J. Willebrand factor and ristocetin. II. Relationship between Willebrand factor, Willebrand antigen and factor VIII activity. Br J Haematol. 1974 Dec;28(4):579–599. doi: 10.1111/j.1365-2141.1974.tb06676.x. [DOI] [PubMed] [Google Scholar]
  24. Nieto M., Perkins H. R. Physicochemical properties of vancomycin and iodovancomycin and their complexes with diacetyl-L-lysyl-D-alanyl-D-alanine. Biochem J. 1971 Aug;123(5):773–787. doi: 10.1042/bj1230773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Nieto M., Perkins H. R. The specificity of combination between ristocetins and peptides related to bacterial cell wall mucopeptide precursors. Biochem J. 1971 Oct;124(5):845–852. doi: 10.1042/bj1240845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Perkins H. R., Nieto M. The chemical basis for the action of the vancomycin group of antibiotics. Ann N Y Acad Sci. 1974 May 10;235(0):348–363. doi: 10.1111/j.1749-6632.1974.tb43276.x. [DOI] [PubMed] [Google Scholar]
  27. Seaman G. V. Electrochemical features of platelet interactions. Thromb Res. 1976 May;8(2 Suppl):235–246. doi: 10.1016/0049-3848(76)90066-9. [DOI] [PubMed] [Google Scholar]
  28. Seaman G. V., Vassar P. S. Changes in the electrokinetic properties of platelets during their aggregation. Arch Biochem Biophys. 1966 Oct;117(1):10–17. doi: 10.1016/0003-9861(66)90119-6. [DOI] [PubMed] [Google Scholar]
  29. Shapiro G. A., Andersen J. C., Pizzo S. V., McKee P. A. The subunit structure of normal and hemophilic factor VIII. J Clin Invest. 1973 Sep;52(9):2198–2210. doi: 10.1172/JCI107405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Smith G. A., Smith K. A., Williams D. H. Structural studies on the antibiotic vancomycin: Evidence for the presence of modified phenylglycine and beta-hydroxytyrosine units. J Chem Soc Perkin 1. 1975;(21):2108–2115. doi: 10.1039/p19750002108. [DOI] [PubMed] [Google Scholar]
  31. Smith K. A., Williams D. H., Smith G. A. Structural studies on the antibiotic vancomycin; the nature of the aromatic rings. J Chem Soc Perkin 1. 1974;(20):2369–2376. [PubMed] [Google Scholar]
  32. Weiss H. J., Rogers J., Brand H. Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII. J Clin Invest. 1973 Nov;52(11):2697–2707. doi: 10.1172/JCI107464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Weiss H. J., Tschopp T. B., Baumgartner H. R., Sussman I. I., Johnson M. M., Egan J. J. Decreased adhesion of giant (Bernard-Soulier) platelets to subendothelium. Further implications on the role of the von Willebrand factor in hemostasis. Am J Med. 1974 Dec;57(6):920–925. doi: 10.1016/0002-9343(74)90170-3. [DOI] [PubMed] [Google Scholar]
  34. Zucker M. B., Kim S. J., McPherson J., Grant R. A. Binding of factor VIII to platelets in the presence of ristocetin. Br J Haematol. 1977 Apr;35(4):535–549. doi: 10.1111/j.1365-2141.1977.tb00619.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES